ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0180

Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta-analysis and Systematic Review

Shivani Garg1, Brianna Boderman2, Nadia Sweet2, Daniel Montes3, Brad Astor2, S. Sam Lim4 and Christie M. Bartels2, 1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 2University of Wisconsin, School of Medicine and Public Health, Madison, WI, 3Mayo Clinic, Rochester, MN, 4Emory University, Atlanta, GA

Meeting: ACR Convergence 2023

Keywords: Access to care, Disparities, Lupus nephritis, Mortality, socioeconomic factors

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 12, 2023

Title: (0176–0195) Healthcare Disparities in Rheumatology Poster I: Lupus

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Lupus results in 58% more organ damage in people of Black race in the US compared to African descendants living in 11 other developed countries. This highlights that social determinants of health (SDH) likely contribute to disparities in LN outcomes in the US. However, the overall burden of adverse SDHs on LN outcomes and how each SDH domain contributes to observed health disparities have not been fully examined. In the absence of such information, health disparities between racial/ethnic groups may be interpreted as inherently “biological” or “cultural” differences. Thus, there is a need to understand the underlying mechanisms explaining how SDHs influence outcomes and contribute to health disparities in LN to advance equity. Objectives of this systematic review and meta-analysis were to: 1) determine the odds of poor LN outcomes in patients with i) any adverse SDHs, and ii) specific SDH domains; 2) develop a framework for the multidimensional impact of SDH on LN outcomes.

Methods: A comprehensive search was performed using MeSH headings and keywords (e.g., lupus nephritis, insurance, poverty, neighborhood socio-economic status, death, etc.) in Medline, Embase, CINAHL and Web of Science. We included observational and interventional studies on human subjects measuring associations between SDHs and LN outcomes. Risk of bias was assessed using standard tools for all studies.

We examined pooled odds of severe LN outcomes (primary outcome) including mortality, end-stage kidney disease (ESKD), or cardiovascular disease (CVD) in patients with and without any adverse SDHs using a random effects model. Additionally, we calculated the pooled odds of poor outcomes by each SDH domain: individual (e.g., race, insurance), healthcare (e.g., fragmented care, hospital experience), community (e.g., neighborhood socioeconomic status), and behavioral (e.g., smoking) (Fig. 1). Heterogeneity was assessed using I2.

Results: Among 531 manually reviewed abstracts, 31 met inclusion. Only 13 studies comparing LN outcomes in patients with and without adverse SDHs were included in the meta-analysis. Overall 92% of studies had low risk of bias. The pooled odds of poor outcomes (death, ESKD, or CVD) in patients with any adverse SDHs were 45% higher compared to those without any adverse SDHs (OR 1.45, 95% CI 1.10-1.91, p = 0.008, I2 85%, Fig. 2). Among the four SDH domains, 64% and 77% higher odds of poor outcomes were noted in patients with adverse SDHs in individual and healthcare domains (OR 1.64, 95% CI 1.13-2.39, I2 92%; OR 1.77, 95% CI 1.2-3.0, I2 0%; Fig. 3A-D). Our framework highlighted a multiplicative impact of adverse SDHs in different domains on poor LN outcomes (Fig. 1). As illustrated in Fig. 1, patients of Black race with fragmented care and public insurance had 12-fold higher odds of mortality/ESKD.

Conclusion: Our study reports a strong negative impact of adverse SDHs on LN outcomes, with the worst impact in patients with adverse individual and healthcare SDH domains. Moreover, having adverse SDHs in ≥2 domains had a multiplicative impact leading to 12-fold higher odds of poor outcomes, widening health disparities in LN. These findings could guide future health-equity focused interventions to address outcome disparities in LN.

Supporting image 1

Fig. 1 Conceptual model highlighting the impact of adverse individual, community, healthcare, and behavioral SDHs on severe LN outcomes. Data in row B. illustrate multiplicative effects of SDH on LN outcomes.

Supporting image 2

Fig. 2. Forest plot showing the odds of ESKD or death in patients with or without any adverse social determinants of health

Supporting image 3

Figure 3. Forest plot showing the odds of ESKD or death with or without adverse social determinants of health in each SDH domain


Disclosures: S. Garg: None; B. Boderman: None; N. Sweet: None; D. Montes: None; B. Astor: None; S. Lim: None; C. Bartels: Pfizer, 5.

To cite this abstract in AMA style:

Garg S, Boderman B, Sweet N, Montes D, Astor B, Lim S, Bartels C. Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta-analysis and Systematic Review [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/multiplicative-impact-of-adverse-social-determinants-of-health-on-outcomes-in-lupus-nephritis-a-meta-analysis-and-systematic-review/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multiplicative-impact-of-adverse-social-determinants-of-health-on-outcomes-in-lupus-nephritis-a-meta-analysis-and-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology